Delivery Order SPE2DB24D1205-SPE2DB25FCZWK
- Not listed
- The Defense Logistics Agency awarded a $1,849.00 delivery order to AmerisourceBergen Drug Corp for VERQUVO 2.5 mg tablets (30 count) on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed-price delivery order carries no set-aside designation and represents a competitively awarded transaction under AmerisourceBergen's existing contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a $2,886.90 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Verquvo 2.5 mg tablets (30-count units). This firm fixed price, non-set-aside contract is expected to be completed by August 18, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $3,721.73 to AmerisourceBergen Drug Corp for Verquvo 5 mg tablets (14-count packaging) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order is non-set-aside and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this requirement as...
- This federal contract award, valued at $1,354.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a Delivery Order for the supply of VERQUVO 2.5 MG TABLET 30S, with an ultimate completion date of January 6, 2025. The contract is a Firm Fixed Price arrangement and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
- This federal contract award, valued at $2,854.78, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of VERQUVO 5 MG TABLET 30S, a pharmaceutical product, and has an ultimate completion date of June 10, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type. The contract was not designated with a set-aside requirement, indicating open...
- This is a $1,998.87 firm fixed-price delivery order contract awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) on June 6, 2025. The contract is for the delivery of VERQUVO 2.5 MG TABLET 30S, a pharmaceutical product, with a period of performance through June 9, 2025. The contract is not set aside and is an open competition award. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,467.93 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the U.S. Department of Defense. The contract is for the supply of VERQUVO 2.5 MG TABLET 30S, a pharmaceutical product, with a period of performance through May 22, 2024. AmerisourceBergen holds a significant $999,999,999...
- This delivery order awards AmerisourceBergen Drug Corp a firm fixed-price contract valued at $1,049.21 for the supply of Verquvo 2.5 mg tablets (30-count) under a competitive, non-set-aside procurement. The Defense Logistics Agency, which manages pharmaceutical supply chains for the Department of Defense, issued this award with an ultimate completion date of August 8, 2025. The contractor will perform this delivery from its corporate office in Conshohocken, Pennsylvania, where...
- This federal contract award, valued at $20,637.44, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of VERQUVO 5 MG TABLET 30S, a pharmaceutical product, with a completion date of December 20, 2024. The contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
- This federal contract award, valued at $2,870.07, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the drug product VERQUVO 5 MG TABLET 14S, with an ultimate completion date of February 24, 2025. The contract is a firm fixed-price arrangement and was not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZWKDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,851.91 to AmerisourceBergen Drug Corp for VERQUVO 2.5 mg tablets (30-count supply) on August 25, 2025, with completion scheduled for August 26, 2025. This non-set-aside, firm fixed-price delivery order was competitively awarded and represents a small-value pharmaceutical transaction within the company's broader federal contract portfolio. The award will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00 prime vendor agreement running through December 2026 that serves as the company's comprehensive pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen is a major pharmaceutical distributor providing an extensive range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The company's consistent receipt of competitively awarded delivery orders demonstrates its capability to meet federal procurement standards and its critical role in supplying pharmaceutical products to support military and veteran healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 8/25/25 |